Legal Representation
Attorney
Karl M. Zielaznicki, Esq.
USPTO Deadlines
Next Deadline
105 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
October 29, 2025
Extension Available
Until October 29, 2025
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 13, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 13, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 12, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 12, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 29, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 3, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 3, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 14, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 26, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 16, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 27, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 27, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 4, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
Additional Information
Design Mark
The mark consists of two parallel arrow shapes pointing left adjacent to a larger right-facing arrow shape.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005